| Dr David R Battaglia, MD | |
|
306 E Lancaster Ave Fl 3, Wynnewood, PA 19096-2105 | |
| (610) 649-5033 | |
| (610) 645-5610 |
| Full Name | Dr David R Battaglia |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 306 E Lancaster Ave Fl 3, Wynnewood, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831160787 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD042580L (Pennsylvania) | Primary |
| Entity Name | Main Line Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922077643 PECOS PAC ID: 1951215201 Enrollment ID: O20040308000373 |
News Archive
Giving blood more frequently – up to every 8 weeks for men and every 12 weeks for women – has no major side effects and could help to increase blood stocks, according to the first ever randomised trial of blood donation involving more than 45000 people in England published in The Lancet.
Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
Ceragenix Pharmaceuticals, Inc. ("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health ("NIH") has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.
Brain bleeds called intracerebral hemorrhages remained stable in incidence among all age groups over the past 30 years, but they increased in people 75 and older, according to a new analysis of the Framingham Heart Study. The findings are in JAMA Neurology.
Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David R Battaglia, MD 3803 W Chester Pike, Ste 160, Newtown Square, PA 19073-2336 Ph: (484) 337-1530 | Dr David R Battaglia, MD 306 E Lancaster Ave Fl 3, Wynnewood, PA 19096-2105 Ph: (610) 649-5033 |
News Archive
Giving blood more frequently – up to every 8 weeks for men and every 12 weeks for women – has no major side effects and could help to increase blood stocks, according to the first ever randomised trial of blood donation involving more than 45000 people in England published in The Lancet.
Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
Ceragenix Pharmaceuticals, Inc. ("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health ("NIH") has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.
Brain bleeds called intracerebral hemorrhages remained stable in incidence among all age groups over the past 30 years, but they increased in people 75 and older, according to a new analysis of the Framingham Heart Study. The findings are in JAMA Neurology.
Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.
› Verified 6 days ago
Heather Denean Mahoney, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 E Lancaster Ave Ste 400, Wynnewood, PA 19096 Phone: 610-642-2002 Fax: 610-642-7607 | |
Bree Zeyzus Johns, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 306 E Lancaster Ave Ste 300, Wynnewood, PA 19096 Phone: 484-476-7255 Fax: 484-476-7854 | |
Dr. Kathryn Rose Finley, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 100e Lancaster Ave B11, Wynnewood, PA 19096 Phone: 484-476-2658 Fax: 484-476-3577 | |
Dr. Mitchell Krause, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 917 Honeysuckle Ln, Wynnewood, PA 19096 Phone: 610-667-1578 Fax: 610-808-4700 | |
Dr. Robyn J Baron, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 306 E Lancaster Ave Ste 200, Wynnewood, PA 19096 Phone: 484-565-1293 Fax: 484-476-7855 | |
Dr. Susan M Sandler, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 306 E Lancaster Ave Ste 300, Wynnewood, PA 19096 Phone: 484-476-7255 Fax: 484-476-7854 |